报价延迟最少15分钟:2026/03/28 18:46 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.16 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.35/1.33
|
|
企业价值
591.98M
|
| 资产负债 |
|
每股账面净值
2.63
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
106.47M
|
|
每股收益
0.29
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market. |
